Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Toll-like receptor 9 agonist IMO cooperates with everolimus in renal cell carcinoma by interfering with tumour growth and angiogenesis.

Damiano V, Rosa R, Formisano L, Nappi L, Gelardi T, Marciano R, Cozzolino I, Troncone G, Agrawal S, Veneziani BM, De Placido S, Bianco R, Tortora G.

Br J Cancer. 2013 Apr 30;108(8):1616-23. doi: 10.1038/bjc.2013.153. Epub 2013 Apr 9.

2.

Toll-like receptor 9 agonist IMO cooperates with cetuximab in K-ras mutant colorectal and pancreatic cancers.

Rosa R, Melisi D, Damiano V, Bianco R, Garofalo S, Gelardi T, Agrawal S, Di Nicolantonio F, Scarpa A, Bardelli A, Tortora G.

Clin Cancer Res. 2011 Oct 15;17(20):6531-41. doi: 10.1158/1078-0432.CCR-10-3376. Epub 2011 Sep 2.

3.

Two novel human anti-ErbB2 immunoagents are active on trastuzumab-resistant tumours.

Gelardi T, Damiano V, Rosa R, Bianco R, Cozzolino R, Tortora G, Laccetti P, D'Alessio G, De Lorenzo C.

Br J Cancer. 2010 Feb 2;102(3):513-9. doi: 10.1038/sj.bjc.6605499. Epub 2010 Jan 5.

4.

A novel toll-like receptor 9 agonist cooperates with trastuzumab in trastuzumab-resistant breast tumors through multiple mechanisms of action.

Damiano V, Garofalo S, Rosa R, Bianco R, Caputo R, Gelardi T, Merola G, Racioppi L, Garbi C, Kandimalla ER, Agrawal S, Tortora G.

Clin Cancer Res. 2009 Nov 15;15(22):6921-30. doi: 10.1158/1078-0432.CCR-09-1599. Epub 2009 Nov 10.

5.

Vascular endothelial growth factor receptor-1 contributes to resistance to anti-epidermal growth factor receptor drugs in human cancer cells.

Bianco R, Rosa R, Damiano V, Daniele G, Gelardi T, Garofalo S, Tarallo V, De Falco S, Melisi D, Benelli R, Albini A, Ryan A, Ciardiello F, Tortora G.

Clin Cancer Res. 2008 Aug 15;14(16):5069-80. doi: 10.1158/1078-0432.CCR-07-4905. Epub 2008 Aug 11.

6.

Enzastaurin inhibits tumours sensitive and resistant to anti-EGFR drugs.

Gelardi T, Caputo R, Damiano V, Daniele G, Pepe S, Ciardiello F, Lahn M, Bianco R, Tortora G.

Br J Cancer. 2008 Aug 5;99(3):473-80. doi: 10.1038/sj.bjc.6604493.

7.

Inhibition of mTOR pathway by everolimus cooperates with EGFR inhibitors in human tumours sensitive and resistant to anti-EGFR drugs.

Bianco R, Garofalo S, Rosa R, Damiano V, Gelardi T, Daniele G, Marciano R, Ciardiello F, Tortora G.

Br J Cancer. 2008 Mar 11;98(5):923-30. doi: 10.1038/sj.bjc.6604269. Epub 2008 Mar 4.

8.

Rational combination of targeted therapies as a strategy to overcome the mechanisms of resistance to inhibitors of EGFR signaling.

Bianco R, Damiano V, Gelardi T, Daniele G, Ciardiello F, Tortora G.

Curr Pharm Des. 2007;13(33):3358-67. Review.

PMID:
18045190
9.

TLR9 agonist acts by different mechanisms synergizing with bevacizumab in sensitive and cetuximab-resistant colon cancer xenografts.

Damiano V, Caputo R, Garofalo S, Bianco R, Rosa R, Merola G, Gelardi T, Racioppi L, Fontanini G, De Placido S, Kandimalla ER, Agrawal S, Ciardiello F, Tortora G.

Proc Natl Acad Sci U S A. 2007 Jul 24;104(30):12468-73. Epub 2007 Jul 16.

10.

Rational bases for the development of EGFR inhibitors for cancer treatment.

Bianco R, Gelardi T, Damiano V, Ciardiello F, Tortora G.

Int J Biochem Cell Biol. 2007;39(7-8):1416-31. Epub 2007 May 21. Review.

PMID:
17596994
11.

The rationale for the combination of selective EGFR inhibitors with cytotoxic drugs and radiotherapy.

Tortora G, Gelardi T, Ciardiello F, Bianco R.

Int J Biol Markers. 2007 Jan-Mar;22(1 Suppl 4):S47-52. Review.

PMID:
17520581
12.

The rationale for the combination of selective EGFR inhibitors with cytotoxic drugs and radiotherapy.

Tortora G, Gelardi T, Ciardiello F, Bianco R.

Int J Biol Markers. 2007 S4 - Jan-Mar;22(4):47-52. doi: 10.5301/JBM.2008.3794.

PMID:
28207114

Supplemental Content

Loading ...
Support Center